Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VIVO Cannabis Inc. V.PDA


Primary Symbol: VVCIF

VIVO Cannabis Inc is a Canada-based company. It is involved in the production and sale of medical and recreational cannabis and the provision of cannabis-related medical information and services in Canada. The company's operating segment includes Cannabis, Patient Clinics, and Corporate. It generates maximum revenue from the Cannabis segment. The company has a presence across three geographical locations - Canada, Germany, and Australia.


OTCQB:VVCIF - Post by User

Post by jfogarty12on Mar 19, 2020 6:15pm
100 Views
Post# 30828415

a small trend?

a small trend?Cannabis sector broadly moves higher after BofA report suggests sales spiking during COVID-19 

Cannabis stocks are trading in the green on Thursday following the release of a report that suggests that people are stocking up on cannabis amid the COVID-19 outbreak. Bank of America analyst Chris Carey said that sales of U.S. and Canadian cannabis are increasing over the past week, a sign that the pot sector may actually be a defensive play in current market conditions. Carey also states that Aphria may see its market share in Canada rise as its peers may struggle to move product. Carey boosted Aphria's rating to a 'buy' despite lowering his price target to $5 a share. 
<< Previous
Bullboard Posts
Next >>